Inhibrx Biosciences (INBX) reported third-quarter 2026 revenue of $2.0 million and a net loss of $38.7 million, or $2.46 per share basic and diluted. The revenue came from a Pfizer license agreement and compared with no revenue in the prior-year quarter.
Cash and cash equivalents totaled $199.5 million as of September 30, 2026. The company is advancing ozekibart and ordastobart clinical programs, with several planned data updates and trial milestones.
- Third-quarter R&D expense was $26.0 million, down from $28.5 million a year earlier.
- General and administrative expense was $7.8 million, compared with $5.3 million in the prior-year quarter.
- Total other expense was $7.0 million, versus $1.4 million a year earlier.
- Inhibrx plans to present updated Phase 1/2 ozekibart data in refractory Ewing sarcoma at the CTOS meeting November 19-20, 2026.
- Initial readouts for the Phase 2 HexAgon study in HNSCC and the Phase 1/2 NSCLC study are expected around mid-2027.
$INBX Insider Trading Activity
$INBX insiders have traded $INBX stock on the open market 25 times in the past 6 months. Of those trades, 20 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $INBX stock by insiders over the last 6 months:
- MARK LAPPE (Chief Executive Officer) has made 16 purchases buying 45,040 shares for an estimated $4,493,159 and 0 sales.
- JON FAIZ KAYYEM has made 3 purchases buying 15,000 shares for an estimated $1,567,580 and 0 sales.
- DOUGLAS FORSYTH purchased 2,500 shares for an estimated $286,617
- KIMBERLY MANHARD has made 0 purchases and 5 sales selling 2,500 shares for an estimated $279,010.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$INBX Hedge Fund Activity
We have seen 101 institutional investors add shares of $INBX stock to their portfolio, and 81 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 808,458 shares (+2473.6%) to their portfolio in Q2 2026, for an estimated $76,601,395
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 726,281 shares (-98.9%) from their portfolio in Q3 2026, for an estimated $72,686,202
- SCHONFELD STRATEGIC ADVISORS LLC added 442,759 shares (+173.7%) to their portfolio in Q2 2026, for an estimated $41,951,415
- VIKING GLOBAL INVESTORS LP removed 313,776 shares (-21.8%) from their portfolio in Q2 2026, for an estimated $29,730,276
- PARKMAN HEALTHCARE PARTNERS LLC added 256,950 shares (+inf%) to their portfolio in Q2 2026, for an estimated $24,346,012
- GOLDMAN SACHS GROUP INC added 243,102 shares (+255.7%) to their portfolio in Q2 2026, for an estimated $23,033,914
- MILLENNIUM MANAGEMENT LLC removed 180,660 shares (-55.1%) from their portfolio in Q2 2026, for an estimated $17,117,535
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
